louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT05150470: Evaluation of the Dental Movements Caused by Oral Appliance in Sleep Apnea Syndrome
Official title: Evaluation of the Dental Movements Caused by Oral Appliance in Syndrome Sleep Apnea Syndrome(DPOAM)
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Sleep Apnea Syndromes
Keywords: oral appliance
dental movement
Lead sponsor: Centre Hospitalier de Valence
Sponsor class: OTHER
Collaborators: name: Claude Bernard University
First posted: 2021-12-09
Enrollment: 180
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Intervention model description: cohort
Primary purpose: PREVENTION

Brief summary: The DO OAM study is a mono-center, interventional, prospective study carried out in CH VALENCE.

It will estimate the prevalence of dental movements in patients treated by oral Appliance for Sleep Apnea syndrome.

The investigators will used fingerprinting technique by taking multiple photographs of the teeth that allow for the three-dimensional reconstruction of the teeth

this study will provide a better understanding of dental movement caused by oral appliance

Detailed description: oral appliances are indicated for the treatment of Sleep Apnea syndrome. Dentoskeletal effects of oral Appliance are imperfectly assessed.

the investigators want to study dental movements by comparing three-dimensional reconstruction of the teeth and the dental articulation in patients treated for sleep apnea syndrome in our Hospital.

The study consists of an additional acquisition of three-dimensional reconstruction of teeth.

the data previously acquired during the first digital impression according usual practise will be compared to this additional acquisition.

Eligibility criteria: Inclusion Criteria:

* Patient with a diagnosis of sleep apnea syndrome treated by Oral appliances in CH Valence
* Availability of previous digital impressions required for Oral appliances manufacturing
* Age ≥ 18 years old
* Read, write and understand the French language

Exclusion Criteria:

* Patient under guardianship, deprived of liberty, safeguard of justice
* Refusal to participate in research

Primary outcomes:
measure: dental movement
timeFrame: 1 DAY at inclusion visit only
Secondary outcomes:
Other outcomes:
Locations:
city: Valence
country: France
facility: Ch Valence
Study officials:
affiliation: CH VALENCE
name: Guillaume Buiret
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04475770: Effect of SNAGs on Stiffness of Lumbar Stabilizer Muscles
Official title: Effect of Sustained Natural Apophyseal Glides on Stiffness of Lumbar Stabilizer Muscles in Non-specific Low Back Pain Individuals
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Low Back Pain
Manuel Therapy
Lead sponsor: Istinye University
Sponsor class: OTHER
First posted: 2020-07-17
Enrollment: 30
Sex: ALL
Minimum age (years): 18
Maximum age (years): 24
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Low back pain is a common health problem worldwide. Epidemiological studies have shown that 70-80% of all people are affected at least once in their lifetime. Although it is common, often the cause of the pain has not been determined and is called 'nonspecific low back pain.

Low back pain has been shown to alter the structure of deep and superficial muscles such as multifidus and erector spinae. However, it has not been fully explained how changes in muscle fiber structure affect the biomechanical properties and functions of the muscle.

There are various manual therapy techniques in the treatment of low back pain. Manual therapists use treatment modalities that include passive techniques such as mobilization and manipulation. Mobilization with movement (MWM) developed by Mulligan involves applying a sustained transverse glide to the spinous process of a vertebra while actively or passively performing. These techniques have gained the name "Sustained Natural Apophyseal Glides" (SNAGS) as it is maintained at the pain-free range and follows the plane of the apophyseal joints under treatment.

Ultrasound shear wave elastography (SWE) provides an advantage since it can quantitatively assess tissue elasticity of in vivo skeletal muscles through non-invasive high-frequency ultrasound waves.

The aim of this study was to investigate the acute effect of Mulligan SNAGs on the stiffness of muscle tissue by using Ultrasound shear wave elastography which is an objective assessment technique.


Eligibility criteria: Inclusion Criteria:

* patients who diagnosed with non-specific low back pain
* between the ages of 18-24
* patients who able to perform at least 40° of trunk flexion

Exclusion Criteria:

* patients who obese, pregnant, had specific low back pain
* indication for surgery in the past 1 year
* the trauma of lumbar region, and systemic inflammatory disease affecting this area
* exercise and conventional physiotherapy in the last 6 months

Primary outcomes:
measure: muscle stiffness
timeFrame: 4 weeks
Secondary outcomes:
measure: The sit and reach test
timeFrame: 4 weeks
measure: Visual Analogue Scale
timeFrame: 4 weeks
measure: The Functional Reach Test
timeFrame: 4 weeks
measure: The Flamingo Balance Test
timeFrame: 4 weeks
measure: Lateral bridge test
timeFrame: 4 weeks
measure: Trunk extensor endurance
timeFrame: 4 weeks
measure: The Oswestry Disability Index
timeFrame: 4 weeks
Other outcomes:
Locations:
city: Istanbul
country: Turkey
facility: Istinye University
state: Eyalet/Yerleşke
Study officials:
References:
Clinical trial NCT02693470: The Difference of Microparticles in Patients With Psoriasis Vulgaris Who Received Stelara(Ustekinumab)
Official title: The Difference of Circulating Endothelial-derived and Platelet-derived Microparticles in Patients With Psoriasis Successfully Treated With Stelara(Ustekinumab)
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE4
Conditions: Psoriasis With Cell-derived Microparticles
Lead sponsor: Chang Gung Memorial Hospital
Sponsor class: OTHER
First posted: 2016-02-26
Enrollment: 100
Sex: ALL
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: Background: Psoriasis, a common inflammatory disease, is associated with atherosclerotic vascular diseases, including stroke, myocardial infarction, and impaired microcirculations, among which circulating microparticles play an important role. In severe psoriasis, there are increased endothelial- and platelet- microparticles that are reduced by TNF-α blockers in parallel with clinical improvement. However, whether Stelara(ustekinumab) treatment would decrease the level of microparticles remains unknown.

Objective: The investigators will evaluate the level of microparticles among normal control, severe psoriasis before and 4 months after ustekinumab treatment.

Detailed description: Methods: The investigators will recruit 50 patients with severe psoriasis who received ustekinumab and 50 control subjects without psoriasis from August 2014 to July 2016. Concentrations of microparticles with expression for surface markers (Annexin V, CD31, and CD41a) will be measured in peripheral blood using flow cytometry.

Eligibility criteria: Inclusion Criteria:

* Patients with severe psoriasis who receive ustekinumab treatment.
* Patients in the control group are examined thoroughly to make sure no psoriatic lesions by two dermatologists. Age, sex, lipid profiles, and blood pressure are recorded for all subjects.

Exclusion Criteria:

* The psoriatic patients and healthy controls who have pregnancy or infection (such as tuberculosis or sepsis) are excluded.

Primary outcomes:
measure: The difference of CD41a and CD31 positive microparticles in patients with severe psoriasis before and after ustekinumab treatment.
timeFrame: The levels of CD41a and CD31 positive microparticles are checked in patients with psoriasis before and 4 months after ustekinumab.
Secondary outcomes:
measure: The difference of CD41a and CD31 positive microparticles between normal control and patients with severe psoriasis
timeFrame: Patients with severe psoriasis: microparticles are checked at baseline. Control group: microparticles are checked at baseline.
Other outcomes:
Locations:
city: Kaohsiung
country: Taiwan
facility: Department of Dermatology, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, Taiwan
Study officials:
affiliation: Chang Gung Memorial Hospital
name: Chih-Hung Lee, M.D.PhD
role: STUDY_DIRECTOR
References: